{"organizations": [], "uuid": "b2c40e3f4241dc9265b667ef25b60f2fda975f36", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180116.html", "section_title": "Archive News &amp; Video for Tuesday, 16 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-eiger-biopharma-says-phase-2-liber/brief-eiger-biopharma-says-phase-2-liberty-study-in-pulmonary-arterial-hypertension-did-not-meet-main-goal-idUSFWN1PB0TU", "country": "US", "domain_rank": 408, "title": "BRIEF-Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.353, "site_type": "news", "published": "2018-01-16T21:12:00.000+02:00", "replies_count": 0, "uuid": "b2c40e3f4241dc9265b667ef25b60f2fda975f36"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-eiger-biopharma-says-phase-2-liber/brief-eiger-biopharma-says-phase-2-liberty-study-in-pulmonary-arterial-hypertension-did-not-meet-main-goal-idUSFWN1PB0TU", "ord_in_thread": 0, "title": "BRIEF-Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal", "locations": [], "entities": {"persons": [{"name": "libert", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eiger biopharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 16 (Reuters) - Eiger Biopharmaceuticals Inc:\n* EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT\n* EIGER BIOPHARMACEUTICALS INC - EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT\n* EIGER BIOPHARMACEUTICALS INC - END OF PHASE 2 MEETING SCHEDULED FOR HDV IN FEBRUARY 2018\n* EIGER BIOPHARMACEUTICALS INC - NO SAFETY SIGNALS ATTRIBUTED TO UBENIMEX WERE IDENTIFIED IN PRELIMINARY ANALYSIS\n* EIGER BIOPHARMACEUTICALS - FURTHER ANALYSIS OF DATA, INCLUDING BIOMARKERS IS ONGOING, ALTHOUGH CO TO DISCONTINUE DEVELOPMENT OF UBENIMEX IN PAH\n* EIGER BIOPHARMACEUTICALS INC - WILL CONTINUE TO DEVELOP UBENIMEX FOR LYMPHEDEMA BASED ON ITS DISTINCT MECHANISM OF ACTION IMPACTING LYMPHANGIOGENESIS\n* EIGER BIOPHARMACEUTICALS INC - EIGER IS DEVELOPING UBENIMEX FOR LYMPHEDEMA IN ULTRA STUDY Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-16T21:12:00.000+02:00", "crawled": "2018-01-17T20:07:58.001+02:00", "highlightTitle": ""}